BR112018074147A2 - tratamento de doenças colestáticas intra-hepáticas - Google Patents

tratamento de doenças colestáticas intra-hepáticas

Info

Publication number
BR112018074147A2
BR112018074147A2 BR112018074147-7A BR112018074147A BR112018074147A2 BR 112018074147 A2 BR112018074147 A2 BR 112018074147A2 BR 112018074147 A BR112018074147 A BR 112018074147A BR 112018074147 A2 BR112018074147 A2 BR 112018074147A2
Authority
BR
Brazil
Prior art keywords
treatment
intrahepatic cholestatic
cholestatic diseases
diseases
intrahepatic
Prior art date
Application number
BR112018074147-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Boudes Pol
A. Mcwherter Charles
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of BR112018074147A2 publication Critical patent/BR112018074147A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018074147-7A 2016-05-31 2017-04-26 tratamento de doenças colestáticas intra-hepáticas BR112018074147A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
US62/343,688 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
BR112018074147A2 true BR112018074147A2 (pt) 2019-03-06

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074147-7A BR112018074147A2 (pt) 2016-05-31 2017-04-26 tratamento de doenças colestáticas intra-hepáticas

Country Status (27)

Country Link
US (5) US10272058B2 (OSRAM)
EP (1) EP3463328B1 (OSRAM)
JP (1) JP7079735B2 (OSRAM)
KR (1) KR102408288B1 (OSRAM)
CN (1) CN109195594A (OSRAM)
AU (1) AU2017274293B2 (OSRAM)
BR (1) BR112018074147A2 (OSRAM)
CA (1) CA3024155C (OSRAM)
CY (1) CY1125465T1 (OSRAM)
DK (1) DK3463328T3 (OSRAM)
ES (1) ES2921230T3 (OSRAM)
HR (1) HRP20220903T1 (OSRAM)
HU (1) HUE059838T2 (OSRAM)
IL (1) IL263372B2 (OSRAM)
LT (1) LT3463328T (OSRAM)
MX (1) MX390417B (OSRAM)
NZ (1) NZ748721A (OSRAM)
PL (1) PL3463328T3 (OSRAM)
PT (1) PT3463328T (OSRAM)
RS (1) RS63345B1 (OSRAM)
RU (1) RU2765460C2 (OSRAM)
SG (1) SG11201810123SA (OSRAM)
SI (1) SI3463328T1 (OSRAM)
SM (1) SMT202200471T1 (OSRAM)
UA (1) UA122719C2 (OSRAM)
WO (1) WO2017209865A1 (OSRAM)
ZA (1) ZA201808360B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
DK4225291T3 (da) * 2021-02-01 2024-05-27 Cymabay Therapeutics Inc Behandling af cholangiopati med seladelpar

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JP4293636B2 (ja) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
ES2399721T5 (es) 2004-03-05 2016-05-25 Univ Pennsylvania Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20130073884A (ko) 2010-03-30 2013-07-03 노파르티스 아게 Dgat1 억제제의 용도
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
WO2015200580A1 (en) 2014-06-26 2015-12-30 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3973959B8 (en) 2017-09-26 2025-01-15 CymaBay Therapeutics, Inc. Treatment of cholestatic pruritus with seladelpar
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
JP7079735B2 (ja) 2022-06-02
US10272058B2 (en) 2019-04-30
AU2017274293A1 (en) 2018-12-13
CY1125465T1 (el) 2025-05-09
HRP20220903T1 (hr) 2022-10-14
MX2018014915A (es) 2019-04-24
CA3024155A1 (en) 2017-12-07
RU2018146504A (ru) 2020-07-09
IL263372A (en) 2018-12-31
EP3463328A1 (en) 2019-04-10
HUE059838T2 (hu) 2023-01-28
NZ748721A (en) 2022-04-29
PT3463328T (pt) 2022-07-07
AU2017274293B2 (en) 2022-03-31
US20170340589A1 (en) 2017-11-30
EP3463328B1 (en) 2022-06-15
US20210220305A1 (en) 2021-07-22
RS63345B1 (sr) 2022-07-29
KR102408288B1 (ko) 2022-06-10
ES2921230T3 (es) 2022-08-22
SI3463328T1 (sl) 2022-08-31
US20200061006A1 (en) 2020-02-27
RU2765460C2 (ru) 2022-01-31
UA122719C2 (uk) 2020-12-28
JP2019518022A (ja) 2019-06-27
US10813895B2 (en) 2020-10-27
PL3463328T3 (pl) 2022-10-03
SG11201810123SA (en) 2018-12-28
US20190255004A1 (en) 2019-08-22
KR20190015363A (ko) 2019-02-13
MX390417B (es) 2025-03-20
US10478411B2 (en) 2019-11-19
ZA201808360B (en) 2020-02-26
US20210000774A1 (en) 2021-01-07
US11596614B2 (en) 2023-03-07
DK3463328T3 (da) 2022-07-04
CA3024155C (en) 2023-10-10
IL263372B2 (en) 2023-06-01
US11000494B2 (en) 2021-05-11
CN109195594A (zh) 2019-01-11
WO2017209865A1 (en) 2017-12-07
SMT202200471T1 (it) 2023-01-13
RU2018146504A3 (OSRAM) 2020-07-27
LT3463328T (lt) 2022-08-10

Similar Documents

Publication Publication Date Title
MX369921B (es) Tratamiento de la hgna y ehna.
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
PT3086637T (pt) Animais não humanos com um gene de cluster de diferenciação 47 humanizado
HRP20181194T1 (hr) Farmaceutski pripravci za liječenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
MX2020007273A (es) Tratamiento del prurito colestasico.
EP3448263A4 (en) Electrotherapeutic treatment
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EP3752180A4 (en) METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
BR112018074147A2 (pt) tratamento de doenças colestáticas intra-hepáticas
EP3273955A4 (en) TREATMENT OF RESPIRATORY DISEASES
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA42930A (fr) Traitement de maladies neurodégénératives
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
HRP20190595T1 (hr) Ventil za primjenu terapije s više lijekova u obliku tekućina
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
PL3458067T3 (pl) Leczenie chorób neurologicznych
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]